AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17188851 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized regression neural network (GRNN) analysis
Number of subjects: 0
Study 17188851 — intervention group
Group type: COMPARATOR
Intervention: Currently accepted compendial methodology
Number of subjects: 0
Study 14681342 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 5 mg
Number of subjects: 32
Study 14681342 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 >20 mg
Number of subjects: 32
Study 14681342 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 50 mg
Number of subjects: 32
Study 14681342 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 100 mg
Number of subjects: 32
Study 14681342 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 (all doses)
Number of subjects: 32
Study 14681342 — intervention group
Group type: EXPERIMENTAL
Intervention: SPP301 metabolite
Number of subjects: 32
Study 11694611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin‐multimineral plus iron
Number of subjects: 150
Study 11694611 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin‐multimineral plus placebo
Number of subjects: 150
Study 11694611 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 150
Study 11694611 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus iron
Number of subjects: 150
Study 9443526 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg i.v. naloxone
Number of subjects: 10
Study 9443526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8494665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine 500 mg twice daily for 5 days
Number of subjects: 0
Study 8494665 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 250 mg three times daily for 5 days
Number of subjects: 0
Study 8494665 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin 250 mg four times daily for 5 days
Number of subjects: 0
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meglumine diatrizoate
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine iodamide
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meglumine ioxaglate
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 23
Study 2952150 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 23
Study 2952150 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 23
Study 2952150 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 23
Study 30161291 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2618960 (0.6 mg kg–1)
Number of subjects: 18
Study 30161291 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2618960 (2.0 mg kg–1)
Number of subjects: 18
Study 30161291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28419841 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered 1% lidocaine with 1:100,000 Epi
Number of subjects: 24
Study 28419841 — intervention group
Group type: COMPARATOR
Intervention: Nonbuffered 2% lidocaine with 1:100,000 Epi
Number of subjects: 24
Study 25907945 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg celecoxib (group A)
Number of subjects: 150
Study 25907945 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg Sou‐Medrol (group B)
Number of subjects: 150
Study 25907945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 150
Study 23107610 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal posturing during labor
Number of subjects: 220
Study 23107610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no maternal posturing)
Number of subjects: 220
Study 21715516 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate-dairy (AD) diet (3.5 daily servings)
Number of subjects: 40
Study 21715516 — intervention group
Group type: COMPARATOR
Intervention: Low-dairy (LD) diet (<0.5 daily servings)
Number of subjects: 40
Study 19340462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine sponge soaked with a 10 mg morphine hydrochloride solution placed in the iliac region for local opiate therapy.
Number of subjects: 20
Study 19340462 — intervention group
Group type: COMPARATOR
Intervention: Intraoperatively centrally administered opiates injected into the contralateral gluteus maximus muscle for systemic therapy.
Number of subjects: 20
Study 19340462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups followed for pain intensity every 2 hours during the first 48 hours and 3 times a day from postoperative days 3-10.
Number of subjects: 20
Study 19340462 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term results at 1, 3, 6, and 12 months postoperatively.
Number of subjects: 20
Study 16442903 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 639
Study 16442903 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 639
Study 14504943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) supplementation (60 g day(‐1))
Number of subjects: 34
Study 14504943 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (WP) supplementation
Number of subjects: 34
Study 11430324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 5742
Study 9747672 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion automated perimetry
Number of subjects: 105
Study 9747672 — intervention group
Group type: COMPARATOR
Intervention: Standard visual field tests
Number of subjects: 105
Study 8150110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, i.v.)
Number of subjects: 12
Study 8150110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, IM)
Number of subjects: 12
Study 8150110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, SC)
Number of subjects: 12
Study 8150110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (150 IU, SC, multiple doses)
Number of subjects: 12
Study 2852038 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory aftercare (contracted to attend four aftercare sessions during the initial 3 months)
Number of subjects: 153
Study 2852038 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary aftercare (participation at clients' discretion)
Number of subjects: 153
Study 2852038 — intervention group
Group type: COMPARATOR
Intervention: No aftercare (dissuaded from attending until fourth month)
Number of subjects: 153
Study 30086484 — intervention group
Group type: EXPERIMENTAL
Intervention: baru almond-enriched diet
Number of subjects: 46
Study 27615557 — intervention group
Group type: EXPERIMENTAL
Intervention: High viral load
Number of subjects: 306
Study 25817472 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife group (misoprostol treatment)
Number of subjects: 1010
Study 25817472 — intervention group
Group type: COMPARATOR
Intervention: Physician group (misoprostol treatment)
Number of subjects: 1010
Study 25817472 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife group
Number of subjects: 1010
Study 25817472 — intervention group
Group type: COMPARATOR
Intervention: Physician group
Number of subjects: 1010
Study 23592533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided puncture
Number of subjects: 208
Study 23592533 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided puncture
Number of subjects: 208
Study 21365025 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaBlast and DynaMatrix
Number of subjects: 9
Study 19108738 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptoglobin phenotype (Hp 1-1, Hp 2-1, Hp 2-2)
Number of subjects: 434
Study 17031012 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 100 mg/day
Number of subjects: 24
Study 17031012 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 400 mg/day
Number of subjects: 24
Study 17031012 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 200 mg/day
Number of subjects: 24
Study 17031012 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol
Number of subjects: 24
Study 12646796 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality condoms
Number of subjects: 38
Study 12646796 — intervention group
Group type: COMPARATOR
Intervention: Male latex condoms
Number of subjects: 38
Study 10676922 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited prednisone treatment followed by WinRho SDF (anti-D) therapy
Number of subjects: 0
Study 10676922 — intervention group
Group type: COMPARATOR
Intervention: Prednisone followed by splenectomy
Number of subjects: 0
Study 8668663 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus)
Number of subjects: 10
Study 8668663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of FK506
Number of subjects: 10
Study 8668663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of FK506
Number of subjects: 10
Study 1979009 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium 0.037 mg kg‐1
Number of subjects: 0
Study 1979009 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium 0.075 mg kg‐1
Number of subjects: 0
Study 1979009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.075 mg kg‐1
Number of subjects: 0
Study 1979009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.09 mg kg‐1
Number of subjects: 0
Study 1979009 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose doxacurium 0.075 mg kg‐1
Number of subjects: 0
Study 7298681 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulphadiazine occlusive dressings
Number of subjects: 64
Study 7298681 — intervention group
Group type: COMPARATOR
Intervention: Fucidin gauze compressive dressings
Number of subjects: 64
Study 31142474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TOC) monotherapy
Number of subjects: 66
Study 31142474 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) with methotrexate (MTX)
Number of subjects: 66
Study 28639008 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 170
Study 28639008 — intervention group
Group type: COMPARATOR
Intervention: Traditional suture
Number of subjects: 170
Study 26402769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive scores from AD Assessment Scale‐Cognitive subscale (ADAS‐Cog) in EXPEDITION study
Number of subjects: 0
Study 26402769 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional scores from AD Cooperative Study‐Activities of Daily Living instrumental subscale (ADCS‐iADL) and Functional Activities Questionnaire (FAQ) in EXPEDITION study
Number of subjects: 0
Study 26402769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive scores from AD Assessment Scale‐Cognitive subscale (ADAS‐Cog) in IDENTITY and ADNI studies
Number of subjects: 0
Study 23732250 — intervention group
Group type: EXPERIMENTAL
Intervention: Any mailed intervention
Number of subjects: 7106
Study 23732250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mailed intervention)
Number of subjects: 7106
Study 21642603 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted 4.2% sodium bicarbonate (50 mL)
Number of subjects: 20
Study 21642603 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (50 mL)
Number of subjects: 20
Study 19202222 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with pegylated interferon and ribavirin in group I (relapsers)
Number of subjects: 29
Study 19202222 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with pegylated interferon and ribavirin in group II (non responders, partial responders, breakthrough non responders)
Number of subjects: 29
Study 17100938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on demand
Number of subjects: 4262
Study 17100938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg three times per week
Number of subjects: 4262
Study 15090126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (TEENS study)
Number of subjects: 16
Study 15090126 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 12577417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanwu hypotensive decoction (SWHD)
Number of subjects: 30
Study 12577417 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 30
Study 9764785 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU daily) and Vitamin C (1000 mg daily)
Number of subjects: 49
Study 9764785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8196374 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-trained teachers (high similarity/low expertise)
Number of subjects: 322
Study 8196374 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside nutrition experts (high expertise/low similarity)
Number of subjects: 322
Study 8196374 — intervention group
Group type: EXPERIMENTAL
Intervention: High communicator similarity/high expertise
Number of subjects: 322
Study 8196374 — intervention group
Group type: EXPERIMENTAL
Intervention: High similarity/low expertise
Number of subjects: 322
Study 8196374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low similarity/high expertise
Number of subjects: 322
Study 8196374 — intervention group
Group type: EXPERIMENTAL
Intervention: Low similarity/low expertise
Number of subjects: 322
Study 8196374 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study 3230347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase removal of the cumulus oophorus; N = 40 oocytes
Number of subjects: 13
Study 3230347 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (control); N = 48 oocytes
Number of subjects: 13
Study 3230347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase removal of the cumulus oophorus in 'no previous fertilization' group
Number of subjects: 13
Study 3230347 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (control) in 'no previous fertilization' group
Number of subjects: 13
Study 3230347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase removal of the cumulus oophorus in immunologic infertility group
Number of subjects: 13
Study 3230347 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (control) in immunologic infertility group
Number of subjects: 13
Study 29650023 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-media food advertising
Number of subjects: 160
Study 29650023 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertising exposure
Number of subjects: 160
Study 29017990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Beyond Pregnancy
Number of subjects: 30
Study 29017990 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 30
Study 24266497 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pen
Number of subjects: 405
Study 24266497 — intervention group
Group type: COMPARATOR
Intervention: Vial-and-syringe
Number of subjects: 405
Study 23588257 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training 3×/week (n=12)
Number of subjects: 32
Study 23588257 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training 5×/week (n=11)
Number of subjects: 32
Study 23588257 — intervention group
Group type: COMPARATOR
Intervention: Control group (0×/week, n=9)
Number of subjects: 32
Study 20059603 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminosalicylates
Number of subjects: 0
Study 20059603 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressants
Number of subjects: 0
Study 20059603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological agents
Number of subjects: 0
Study 20059603 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents
Number of subjects: 0
Study 18082495 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 14700
Study 18082495 — intervention group
Group type: COMPARATOR
Intervention: No amiodarone (Control)
Number of subjects: 14700
Study 16961129 — intervention group
Group type: EXPERIMENTAL
Intervention: GliaSite brachytherapy (60 Gy dose administered to a 1-cm depth after resection)
Number of subjects: 71
Study 16961129 — intervention group
Group type: EXPERIMENTAL
Intervention: GliaSite brachytherapy
Number of subjects: 71
Study 12942656 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention tailored to the patient's stage of readiness to change
Number of subjects: 60
Study 12942656 — intervention group
Group type: COMPARATOR
Intervention: Simple-advice
Number of subjects: 60
Study 12942656 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 10826241 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy (BFST)
Number of subjects: 119
Study 10826241 — intervention group
Group type: COMPARATOR
Intervention: Current Therapy (CT)
Number of subjects: 119
Study 10826241 — intervention group
Group type: COMPARATOR
Intervention: Education and Support Group (ES)
Number of subjects: 119
Study 8793702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise (cycling at 60-70% of maximum workload)
Number of subjects: 60
Study 8793702 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric intake restriction (4186-6279 kl/day, 16 weeks)
Number of subjects: 60
Study 8793702 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity exercise combined with caloric intake restriction
Number of subjects: 60
Study 8793702 — intervention group
Group type: COMPARATOR
Intervention: Control light intensity exercise
Number of subjects: 60
Study 1607191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream (EMLA(R))
Number of subjects: 63
Study 1607191 — intervention group
Group type: COMPARATOR
Intervention: Xylocaine 1% local infiltration
Number of subjects: 63
Study 3518661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES)
Number of subjects: 70
Study 3518661 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 70
Study 31578055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% aroma bath salt
Number of subjects: 35
Study 31578055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% aroma bath salt
Number of subjects: 35
Study 31578055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aroma bath salt
Number of subjects: 35
Study 31578055 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 29045079 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Number of subjects: 2210
Study 29045079 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2210
Study 26985726 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 372
Study 26985726 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 372
Study 25261599 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT) with formal home practice of at least 3 days a week
Number of subjects: 99
Study 25261599 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Number of subjects: 99
Study 22020133 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Stroop task
Number of subjects: 0
Study 22020133 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study 19940856 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver alginate (Algidex) patches
Number of subjects: 50
Study 19940856 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 50
Study 18848350 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent bronchodilator response (BDR)
Number of subjects: 1041
Study 16948966 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for hemoglobinopathies, congenital hypothyroidism, phenylketonuria, and cystic fibrosis
Number of subjects: 0
Study 16948966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision screening
Number of subjects: 0
Study 16948966 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for tuberculosis (TB)
Number of subjects: 0
Study 16948966 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for lead toxicity
Number of subjects: 0
Study 16948966 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity testing
Number of subjects: 0
Study 16948966 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for TB and lead
Number of subjects: 0
Study 12540406 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for 6 weeks
Number of subjects: 20
Study 12540406 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 20
Study 10813108 — intervention group
Group type: EXPERIMENTAL
Intervention: toremifene (40 mg/day; n = 19)
Number of subjects: 44
Study 10813108 — intervention group
Group type: EXPERIMENTAL
Intervention: tamoxifen (20 mg/day; n = 25)
Number of subjects: 44
Study 10813108 — intervention group
Group type: EXPERIMENTAL
Intervention: antiestrogen group (toremifene and tamoxifen)
Number of subjects: 44
Study 8871423 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) model
Number of subjects: 143
Study 8871423 — intervention group
Group type: COMPARATOR
Intervention: Group Skills Training
Number of subjects: 143
Study 1640148 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of methylprednisolone acetate plus local anaesthetic
Number of subjects: 0
Study 1640148 — intervention group
Group type: COMPARATOR
Intervention: Control injection of local anaesthetic
Number of subjects: 0
Study 6879242 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E-group)
Number of subjects: 0
Study 6879242 — intervention group
Group type: COMPARATOR
Intervention: Control group (C-group)
Number of subjects: 0
Study 31289885 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (low or moderate dosage)
Number of subjects: 48